Avenue therapeutics announces reverse stock split and provides regulatory update for iv tramadol including receipt of type a meeting minutes from the fda

New york, sept. 22, 2022 (globe newswire) -- avenue therapeutics, inc. (nasdaq: atxi) (“avenue” or the “company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced that it will effect a 1-for-15 reverse split of its common stock, which will be effective for trading purposes on the nasdaq capital market as of the commencement of trading on september 23, 2022, and also provided a regulatory update related to its intravenous (“iv”) tramadol product candidate.
ATXI Ratings Summary
ATXI Quant Ranking